Ian Rowe comments on data from the landmark work he, Richard Parker and colleagues in Leeds, UK are conducting around the issue of population screening for NASH: “it’s quite easy to show that you can identify more liver disease in the community and you can do so more efficiently.” This short interview goes into detail…
